Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

Inclusion Criteria: * 50 years and older * BCVA ETDRS letter score in study eye between 20-57 letters using ETDRS refraction (Snellen of 20/70-20/400) * Any CNV secondary to AMD in study eye, classic, minimally classic or occult with leakage on fluorescein angiography and intraretinal or subretinal fluid on OCT * Visual acuity in fellow eye must be 20/800 or better at 4 meters * Able to read, understand and sign the consent form before entering into study Exclusion Criteria: * Ocular disease other than CNV that could compromise vision in study eye * Systemic immunosuppressive medication/therapy (e.g., chemotherapy, steroids) * Uncontrolled hypertension and/or arrhythmias * QT/QTc interval measurement \>450 msec * Cancer within the last 2 years except superficial basal or squamous cell skin cancer or cervical carcinoma in situ * Have angioid streaks, presumed ocular histoplasmosis syndrome, myopia (\>8 diopters) or CNV secondary to other causes than AMD * Any additional ocular diseases which have irreversibly compromised visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema and severe non-proliferative diabetic retinopathy * Any intraocular or general surgery, including cataract surgery, within 2 months of Day 1 * History of uveitis in either eye * Any ocular or periocular infection within 4 weeks prior to Day 1 * Active ocular inflammation grade trace and above * Cup to disc ratio \>0.8, IOP \>21 mmHg in glaucoma subjects treated with more than 2 ocular hypotensive agents * Previous pars plana vitrectomy or trabeculectomy in study eye * History of anterior vitrectomy * Inability to obtain photographs, FA or OCT to document CNV, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access * Aphakia * Previous intravitreal Macugen, Avastin or Lucentis (injection or drug device implantation) in study eye within 6 weeks or triamcinolone within 6 months * Receiving or requiring chronic concomitant therapy with systemic anti-angiogenic treatments p.o., parenteral (excluding inhaled steroids) (\>5 mg) or topical corticosteroids in the study eye * PDT within 12 weeks prior to Day 1 * Subjects taking systemic anticoagulants such as warfarin * Investigational agents or devices within 6 weeks prior to Day 1 * Females who are pregnant or nursing and women of child bearing potential who are not using adequate contraceptive precautions